Americana Partners LLC Acquires 46,008 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Americana Partners increased its Bristol Myers Squibb stake by 19.9% in the third quarter, adding 46,008 shares for a total of 277,752 shares valued at approximately $17.3 million. Institutional investors collectively own 76.41% of the company.
• Bristol Myers Squibb exceeded third-quarter expectations, reporting adjusted EPS of $1.35 versus the $1.10 consensus and revenue of $13.07 billion versus $12.72 billion, with revenue up 6.9% year over year.
• Analyst sentiment remains mixed, with the stock carrying a consensus “Hold” rating and an average price target of $65.46. The company also declared a quarterly dividend of $0.63, representing a 4.0% annualized yield.

Americana Partners LLC raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 19.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 277,752 shares of the biopharmaceutical company's stock after purchasing an additional 46,008 shares during the quarter. Americana Partners LLC's holdings in Bristol Myers Squibb were worth $17,332,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb in the 2nd quarter worth about $27,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $32,000. William Mack & Associates Inc. purchased a new stake in shares of Bristol Myers Squibb in the third quarter valued at approximately $35,000. Groupe la Francaise boosted its holdings in shares of Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 501 shares during the period. Finally, Kilter Group LLC bought a new position in Bristol Myers Squibb in the second quarter worth approximately $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on BMY shares. Morgan Stanley reduced their price objective on Bristol Myers Squibb from $41.00 to $40.00 and set an "underweight" rating on the stock in a report on Friday. BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. UBS Group downgraded Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 5th. TD Cowen began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating on the stock. Finally, Truist Financial set a $70.00 price objective on Bristol Myers Squibb in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $65.46.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $62.46 on Friday. The company has a market cap of $127.59 billion, a PE ratio of 13.85, a P/E/G ratio of 0.32 and a beta of 0.19. The firm's 50 day moving average price is $62.80 and its 200-day moving average price is $59.94. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a 52-week low of $45.20 and a 52-week high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.25. The company had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 62.78%. Bristol Myers Squibb's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.63 earnings per share. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.37 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be issued a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.05% of the company's stock.

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.